Umm Al Quwain sits roughly 75km north of Dubai — close enough for a day trip, far enough that driving for a single research order is a poor use of an investigator's afternoon. The peptide research community in the Northern Emirates has grown quietly over the past three years, and the question REVIVE LAB UAE fields most often from UAQ-based clients is simple: can you actually get tesamorelin here within 24 hours, cold? The answer is yes — and this post documents how, why it matters for protocol integrity, and what the published science says about the compound those vials contain.
Tesamorelin is a 44-amino-acid synthetic analog of human growth-hormone-releasing hormone (GHRH 1-44). The key structural feature is a trans-3-hexenoyl modification at the N-terminus, which confers resistance to dipeptidyl peptidase-IV (DPP-IV) — the enzyme that degrades native GHRH within minutes of endogenous release. The modification extends circulating half-life without altering the receptor-binding geometry of the peptide: tesamorelin binds GHRH receptors on pituitary somatotroph cells and drives pulsatile GH release, downstream IGF-1 synthesis, and the downstream metabolic effects researchers are primarily interested in.
The downstream effect that dominates the published literature is selective visceral adipose tissue (VAT) reduction — not total body weight loss, but preferential mobilisation of the deep metabolically active fat depot surrounding the organs. For investigators studying abdominal fat compartments, hepatic steatosis, and GH axis dynamics, this selectivity is the compound's defining research feature. It also explains why dosing references in every major study sit at 1-2 mg/day — the somatotroph response is saturated well below levels that produce systemic supraphysiological GH surges.
REVIVE LAB UAE stocks tesamorelin in 5mg and 10mg vials only — the same formats referenced across all four pivotal trials. Investigators looking to buy tesamorelin UAE in other strengths should know that 1mg or 2mg vials are not part of the published supply chain and are not stocked at REVIVE.
Any research team referencing tesamorelin in a UAQ or Dubai context should be familiar with the four anchor studies. They are the only citations that matter — and the ones REVIVE LAB UAE's research desk cites when investigators ask about the evidence quality behind this compound.
Falutz and colleagues enrolled 412 subjects with HIV-associated lipodystrophy (abdominal fat accumulation) in a randomised, double-blind, placebo-controlled trial. Tesamorelin was administered at 2 mg/day SC for 26 weeks. The primary outcome — VAT measured by CT cross-sectional area — fell by approximately 15-18% in the active arm versus placebo. IGF-1 rose by roughly 50%, confirming engagement of the GH axis. Crucially, the effect was compartment-specific: subcutaneous fat was not preferentially reduced, consistent with tesamorelin's mechanism of preferential splanchnic fat mobilisation. This compartment selectivity remains the feature that separates tesamorelin from general energy-deficit interventions in research contexts.
The same group published a 26-week open-label extension (NEJM 2010) tracking subjects who continued tesamorelin versus those who switched off it. Subjects remaining on active compound maintained VAT reduction; those crossing to placebo regained visceral fat within the extension period. The extension was important for two reasons: it confirmed the effect required ongoing administration to persist, and it provided additional safety data (no meaningful increase in fasting glucose or HbA1c over the longer window) that investigators reviewing protocol safety windows find relevant.
Stanley and colleagues at Massachusetts General Hospital ran a randomised, double-blind trial in HIV-infected patients with abdominal fat accumulation and elevated liver fat measured by MRI spectroscopy. Tesamorelin at 2 mg/day for 12 months produced a 32% reduction in liver fat versus placebo — a finding that drew significant attention because no approved pharmacological agent at the time had demonstrated a comparable liver fat signal in that population without accompanying off-target metabolic effects. The 32% reduction figure (Stanley 2014, JAMA) is the most-cited quantitative outcome from the compound's research history.
The 2019 Lancet HIV paper extended the NAFLD work over a longer follow-up window, tracking fibrosis markers and liver enzyme trends alongside the fat reduction signal. The key takeaway for research teams: the liver fat signal from the 2014 JAMA data was replicated and the safety profile held over 12 months. For investigators designing protocols with a hepatic endpoint, this paper provides the longest durability data currently available for tesamorelin in a controlled setting.
| Study | Journal / Year | n | Dose | Key Finding |
|---|---|---|---|---|
| Falutz et al. | NEJM 2007 | 412 | 2 mg/day SC | VAT -15-18%; IGF-1 +~50% |
| Falutz et al. | NEJM / JCEM 2010 | Extension | 2 mg/day SC | VAT maintained on-drug; reversed off-drug |
| Stanley et al. | JAMA 2014 | 61 | 2 mg/day SC | Liver fat -32% vs placebo |
| Stanley et al. | Lancet HIV 2019 | Multicentre | 2 mg/day SC | 12-month NAFLD confirmation; safety held |
REVIVE LAB UAE stocks two formats. The 5mg vial suits shorter research windows and tighter dosing schedules; the 10mg vial is the more economical choice for investigators running multi-week protocols referencing the Falutz 2mg/day schedule. Below is the standard reconstitution reference table used by the REVIVE research desk.
| Vial | BAC Water Added | Concentration | Volume per 1mg (research ref) |
|---|---|---|---|
| Tesamorelin 5mg | 1 mL | 5 mg/mL | 0.20 mL |
| Tesamorelin 5mg | 2 mL | 2.5 mg/mL | 0.40 mL |
| Tesamorelin 10mg | 2 mL | 5 mg/mL | 0.20 mL |
| Tesamorelin 10mg | 4 mL | 2.5 mg/mL | 0.40 mL |
Storage after reconstitution: 2-8°C, protected from light, use within 14 days. Lyophilized vials as received from REVIVE LAB UAE: 2-8°C refrigeration, shelf-stable up to the lot expiry printed on the COA.
The 75km highway run from Dubai's dispatch hub to Umm Al Quwain takes 50-60 minutes under normal E311 conditions. The real cold-chain challenge is not distance — it is ambient temperature. A July afternoon in UAQ hits 44-46°C on the tarmac, which means an uninsulated courier bag will break 2-8°C within 20-30 minutes. This is why REVIVE LAB UAE uses validated insulated cold-chain packaging: gel packs calibrated to the UAE summer worst-case, not the UK warehouse standard that most offshore peptide shippers use.
Vials leave Dubai in insulated cold-pack mailers rated for 24+ hours at 2-8°C, even against UAE summer ambient temperatures. By the time a vial reaches UAQ — typically 18-24 hours from order confirmation — it arrives within spec, verified by the gel-pack state and optional temperature strip included on request.
| Emirate / Location | Expected Delivery | Cold Chain | Cash on Delivery |
|---|---|---|---|
| Dubai (same-day zones: Marina, JBR, DIFC, Downtown, JVC, Palm, Business Bay) | Same-day, 4-8h | Yes | Yes |
| Sharjah | 8-18h | Yes | Yes |
| Ajman | 18-24h | Yes | Yes |
| Umm Al Quwain (UAQ) | 18-24h | Yes | Yes |
| Ras Al Khaimah (RAK) | 18-24h | Yes | Yes |
| Abu Dhabi (Corniche, Yas, Saadiyat, Reem) | 18-24h | Yes | Yes |
| Fujairah | 24h | Yes | Yes |
| Al Ain | 24h | Yes | Yes |
Orders placed before the daily dispatch cut-off ship the same business day. For UAQ specifically, this means a researcher ordering in the morning will typically receive vials the following morning, cold and in-spec. Tesamorelin same day Dubai is available for same-day zones; UAQ is on the next-day schedule by geography, not by any supply constraint.
Investigators sourcing tesamorelin from offshore suppliers face a compounding cold-chain risk: international air freight handling in Dubai summer adds 12-24 hours of uncontrolled temperature exposure before the parcel even clears customs. Every hour outside 2-8°C post-reconstitution — or above 30°C for lyophilized stock — is a debit against the stability window the Falutz and Stanley protocols assumed. When investigators buy tesamorelin UAE from a locally-stocked supplier like REVIVE LAB UAE, the cold-chain provenance is domestic and auditable from dispatch to door. There is no transatlantic ambient-temperature ambiguity baked into the vial.
REVIVE LAB UAE supplies HPLC-verified, lot-COA, cold-chain dispatched tesamorelin across all 7 emirates — including UAQ, RAK, Fujairah, and Al Ain, not just Dubai. Every batch comes with a lot-specific certificate of analysis confirming purity ≥99% and identity by mass spectrometry. If your research protocol requires COA documentation, it ships with the order.
The REVIVE research desk logs recurring queries from Northern Emirates clients. Three patterns dominate:
A fourth question, less often asked but worth addressing: peptides UAE suppliers vary enormously in what they actually test and what they merely claim. REVIVE LAB UAE publishes HPLC purity data for every lot. If a supplier cannot provide a lot-specific COA within 24 hours of request, the purity claim is marketing, not analytical chemistry.
Yes. REVIVE LAB UAE dispatches tesamorelin 5mg and 10mg vials to Umm Al Quwain (UAQ) within 18-24 hours of order confirmation. Vials are packed in validated cold-chain insulated mailers rated for UAE summer conditions, maintaining 2-8°C throughout the Dubai-to-UAQ transit. Cash on delivery is available and all shipments use plain, unbranded outer packaging by default — no upsell required for discretion.
REVIVE LAB UAE stocks tesamorelin in 5mg and 10mg vials only. These are the same formats used across the pivotal Falutz 2007 (NEJM) and Stanley 2014 (JAMA) research protocols. Each vial is HPLC-verified to ≥99% purity with a lot-specific COA. Research-context dosing references of 1mg or 2mg per day reflect the published literature directly — investigators should calibrate against their own protocol requirements and the primary sources listed below.
Yes. REVIVE LAB UAE supports cash on delivery across all seven emirates. UAQ, Dubai, Abu Dhabi, Sharjah, Ajman, RAK and Fujairah are all covered. Orders placed before the daily cut-off ship the same business day. For tesamorelin Dubai 24h delivery within same-day Dubai zones, orders placed before 2pm typically arrive the same evening. For UAQ, next-day morning arrival is the standard window.